The company’s performance stems from a shift away from traditional agricultural supply chains. By utilizing precision fermentation, NNB produces highly concentrated active compounds—such as dihydroberberine and ketone salts—using yeast and microbes in laboratory settings. This approach bypasses the volatility of standard botanical sourcing, allowing for consistent potency at lower dosages while adhering to clean-label standards.
Chief Brand Officer Dustin Elliot attributes this trajectory to a vertically integrated business model that bridges the gap between raw material innovation and distribution. Unlike competitors limited to one side of the supply chain, NNB tailors its formulations for clients across the functional beverage, cognitive health, and sports nutrition sectors. With the current $20 million Series C round expected to close by March 10, 2026, and a subsequent $20 million Series C+ round planned for later this year, the firm is scaling its manufacturing capabilities to meet rising global demand for science-backed wellness products.





Comments (0)
No comments yet. Be the first!